Kodiak Sciences Inc.
KOD
Pozycja w akcjach
#3232
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Cena akcji
$87.38
Ostatnia synchronizacja: 2026-10-21
Kapitalizacja rynkowa
$5.49B
Zmiana (1 dzień)
-6.01%
Zmiana (1 rok)
384.10%
Kraj
US
Handel Kodiak Sciences Inc. (KOD)
Kategoria
Healthcare
Historia ceny akcji dla Kodiak Sciences Inc. (KOD)
Najwyższa cena zamknięcia: $92.12 dnia 2026-10-01
Najniższa cena zamknięcia: $1.97 dnia 2018-10-01
Najniższa cena zamknięcia: $1.97 dnia 2018-10-01
Historia cen akcji firmy Kodiak Sciences Inc. od 2018 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 40.19% |
| 2025 | 191.32% |
| 2024 | 200.90% |
| 2023 | -58.27% |
| 2022 | -59.80% |
| 2021 | -36.18% |
| 2020 | 106.84% |
| 2019 | 776.39% |
| 2018 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.19 | -4.22% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
